Cervical Cancer
Jul 31, 2018•12 min
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
Persistence of high-grade oncogenic HPV is the key risk factor for the development of cervical carcinoma. In this session, we will review the pathophysiology, clinical staging, and treatment regimens for cervical carcinoma. Additionally, we will review the 2014 approved medication (Avastin) for the treatment of advanced, metastatic, recurrent cervical cancer. (Data taken from the Society of Gynecologic Oncology and the American Cancer Society.
For the best experience, listen in Metacast app for iOS or Android